Here’s why LSD is good for business

Psychedelic-assisted therapy is emerging as a promising treatment for mental health conditions like anxiety, addiction, and PTSD. Here’s why some employers are keen to help their staff get access.

In this episode of The Next Stage, Marik Hazan of psychedelics investment firm Tabula Rasa Ventures and Sherry Rais, CEO of psychedelic therapy provider Enthea discuss research that shows how psychedelics can treat root causes in ways traditional pharmaceuticals can’t, and how some tech companies are starting to cover these therapies for employees.

“It’s really fascinating how enticing an offer it is because employers are seeing that when their employees are suffering from mental health, it’s costing them in terms of absenteeism, it’s costing them in terms of retention, it’s costing them in terms of productivity,” says Sherry.

“Even Fortune 100 companies are open to and interested in offering [psychedelic-assisted therapy coverage],” added the CEO.

Why now? Because burnout and mental health issues are the primary reasons Gen Z and millennials leave work, according to Sherry. Something that has been on the increase since the Covid-19 pandemic.

Marik Hazan and Sherry Rais were in conversation with Colin Leslie, editor-in-chief of Canadian Healthcare Network, on HealthConf at Collision 2023.

Subscribe to 🎙️ The Next Stage 🎙️ wherever you get your podcasts, and download this episode – or listen on the embedded player above right now.

Join us in Lisbon this November for the latest in health and science trends. Get your tickets here.

Main image of an open mouth with extended tongue. The tongue appears to hold an acid tab with a dollar sign design on it: Web Summit